NeuroVive´s project for the treatment of stroke enters new phase with Isomerase Therapeutics

Posted in Awards & Appointments on 14th Aug 2015

ACNRJA15-30bNeuroVive Pharmaceutical, a Swedish biotechnology company focusing on mitochondrial medicine, is entering a new phase in the company´s development project NVP014 for the treatment of ischaemic stroke in collaboration with UK partner Isomerase Therapeutics. The former collaboration with to-BBB of the Netherlands concluded at the end of 2014 and on the basis of the results obtained, NeuroVive is now developing new molecules and a more effective method for penetrating the blood-brain barrier.

The collaboration with Isomerase has already generated new lead compounds that are in pre-clinical evaluation.

“The initiative we’ve now begun with Isomerase Therapeutics is based on the same chemistry platform as our NVP018/NVP019 compounds, which we view as the next generation cyclophilin inhibitor. We’re also developing a new method for improved penetration across the blood-brain barrier,” commented Magnus Hansson, Senior Scientist at NeuroVive.

ACNR 2015;15(3):30.  Online 30/07/15

Download this Article
SIGN UP FOR OUR MAILING LIST

Open Access, for medical professionals: Sign up to receive our email newsletter with links to the latest content. ACNR is free, thanks to the support of advertisers. The editorial content is peer reviewed and remains completely independent unless clearly specified. 

We may infrequently send you news from our sponsors which is relevant to the field of neurology, but you can opt out at any time.

This website is for medical professionals only.